Bevacizumab and osteonecrosis of the jaw: Report of a case and review of the
literature
Maria LAZARIDOU, Vagia GKALITSIOU, Dimitris MALOUTAS, Antonis VOLITAKIS
Private Practice, Thessaloniki, Greece
Hellenic Archives of Oral & Maxillofacial Surgery (2014) 2, 77-86
SUMMARY: Osteonecrosis of the jaws is a severe bone disease. Until recently bisphosphonates were the most common cause of drug-induced osteonecrosis of the jaws. Nowadays other drugs that are used in cancer treatment have been implicated in osteonecrosis of the jaws. One of these drugs is bevacizumab an antiangiogenesis factor, which is used for the treatment of certain types of cancer. The aim of this case report is to present a rare case of osteonecrosis of the mandible caused by the drug bevacizumab and to review the current literature. A 55-year-old male patient suffering from metastatic kidney cancer was treated with bevacizumab and a combination of other chemotherapeutic drugs for a couple of years. The patient presented with osteonecrosis of the left posterior mandible and was treated conservatively with removal of bone sequestra and curettage. The patient was examined again after two weeks and there was a significant improvement. Regular reexaminations were recommended in case of relapse.
KEY WORDS: bevacizumab; osteonecrosis of the jaw; antiangiogenesis factor; avastin.
REFERENCES
Aprile G, Ferrari L, Fontanella C, Puglisi: Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol 12:232-6, 2012 Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F. et al: Recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Pathol Oral Cir Bucal 12(4):E336–340, 2007
Bettini G, Blandamura S, Saia G, Bedogni A: Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. Oct 22; 2012
Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF: Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol 25(3):789-91, 2012
Bouquot JE; Christian J: Long-term effects of jawbone curettage on the pain of facial neuralgia. J Oral Maxillofac Surg 53 (4): 387–97, 1995
Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423(6937):337-42, 2003
Bucu A, Niț ă T, Dincă O, Vlădan C, Bucur M.B: Bisphosphonate associated osteonecrosis of the jaw. Rev chir oro-maxilo-fac implantol 2 (3): 24–27, 2011 Burr DB: Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 7(4):354–355, 2007
Christodoulou C, Pervena A, Klouvas G, Glani E, Falagas ME, Tsakalis G. et al: Combination of biophosphonates and antioangiogenic factors induces osteonecrosis of the jaw more frequently than biophosponates alone. Oncology 76(3):209-11, 2009
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M. et al: VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med 358 (11): 1129–36, 2008
Estilo CL, Fornier M, Farooki A, Carison D, Bohle G 3rd, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26(24):4037-8, 2008 Ferguson W: New treatment of necrosis. Am J Dent Science 1 (series 3): 189, 1868 Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M. et al: VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol 2013 Mar 5. [Epub ahead of print]
Greuter S, Schmid F, Ruhstallet T, Thuerlimann B.: Bevacizumab- associated osteonecrosis of the jaw. Ann Oncol 19 (12):2091-2092, 2008
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I. et al: Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181, 2010
Hopp R.N, Pucci J, Santos-Silva A.R, Jorge J: Osteonecrosis after administration of intravitreous Bevacizumab. J Oral Maxillofac Surg 70:632-635, 2012
Hou J, Tao Y, Jiang YR, Li XX, Gao L: Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: A matched study. Chin Med J122:2695, 2009
Lim JY, Lee SY, Kim JG, Kim JG, Lee JY, Chung H, Yoon YH.l: Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 5 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 90(1):61-7, 2010
Noel HR: A lecture on caries and necrosis of bone. Am J Dent Science1 (3): 425-482, 1868
Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS : Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. [Epub ahead of print] 2012
Ravaud A: New challenges in kidney cancer therapy: bevacizumab. Ann Oncol 9:89, 2007
Rosenfeld PJ: Intravitreal Avastin: The low cost alternative to Lucentis. Am J Ophthalmol 142:141, 2006
Rusovici R, Patel CJ, Chalam KV: Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle. Clinical ophtalmol 7: 321-327, 2013
Santos-Silva AR, Belizario Rosa GA, Castro Junior Gd, Dias RB, Prado Ribeiro AC, Brandao TB: Osteonecrosis of the mandible associated with bvacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 115 (6):e32-6, 2013
Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P: Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital. Can J Neurol Sci 40(2):241-6,2013
Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W. et al: Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. [Epub ahead of print] 2013
Semenza GL: A new weapon for attacking tumor blood vessels. N Engl J Med 358 (19): 2066–7, 2008
Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tetè S, Dolci M: Bevacizumab related ostenecrosis of the jaw. Int J Immunopathol Pharmacol 22(4):1121-3, 2009 Sliesoriaitis S, Tawfik, B: Bevacizumab-induced bowel perforation. J Am Osteop Assoc 111 (7) 437-44, 2011
Troeltzsch Μ, Woodlock Τ, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M: Physiology and Pharmacology of nonbisphosphonate drugs Implicated in osteonecrosis of the jaw. J Can Dent Assoc 78:85, 2012
Van Poznak C: Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer ResTreat 122:189–191, 2010
Xiaolin W, Shen N, Mendoza A, Khnanna C, Helman L: CC1-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of m-TOR/Hil-1α/VEGF Signaling. Neoplasia 8: 394-401, 2006
Private Practice, Thessaloniki, Greece
Hellenic Archives of Oral & Maxillofacial Surgery (2014) 2, 77-86
SUMMARY: Osteonecrosis of the jaws is a severe bone disease. Until recently bisphosphonates were the most common cause of drug-induced osteonecrosis of the jaws. Nowadays other drugs that are used in cancer treatment have been implicated in osteonecrosis of the jaws. One of these drugs is bevacizumab an antiangiogenesis factor, which is used for the treatment of certain types of cancer. The aim of this case report is to present a rare case of osteonecrosis of the mandible caused by the drug bevacizumab and to review the current literature. A 55-year-old male patient suffering from metastatic kidney cancer was treated with bevacizumab and a combination of other chemotherapeutic drugs for a couple of years. The patient presented with osteonecrosis of the left posterior mandible and was treated conservatively with removal of bone sequestra and curettage. The patient was examined again after two weeks and there was a significant improvement. Regular reexaminations were recommended in case of relapse.
KEY WORDS: bevacizumab; osteonecrosis of the jaw; antiangiogenesis factor; avastin.
REFERENCES
Aprile G, Ferrari L, Fontanella C, Puglisi: Bevacizumab in older patients with advanced colorectal or breast cancer. Crit Rev Oncol Hematol 12:232-6, 2012 Bagán J, Blade J, Cozar JM, Constela M, García Sanz R, Gómez Veiga F. et al: Recommendations for the prevention, diagnosis and treatment of osteonecrosis of the jaw (ONJ) in cancer patients treated with bisphosphonates. Med Oral Pathol Oral Cir Bucal 12(4):E336–340, 2007
Bettini G, Blandamura S, Saia G, Bedogni A: Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process. BMJ Case Rep. Oct 22; 2012
Binello P, Bandelloni R, Labanca M, Buffoli B, Rezzani R, Rodella LF: Osteonecrosis of the jaws and bevacizumab therapy: a case report. Int J Immunopathol Pharmacol 25(3):789-91, 2012
Bouquot JE; Christian J: Long-term effects of jawbone curettage on the pain of facial neuralgia. J Oral Maxillofac Surg 53 (4): 387–97, 1995
Boyle WJ, Simonet WS, Lacey DL: Osteoclast differentiation and activation. Nature 423(6937):337-42, 2003
Bucu A, Niț ă T, Dincă O, Vlădan C, Bucur M.B: Bisphosphonate associated osteonecrosis of the jaw. Rev chir oro-maxilo-fac implantol 2 (3): 24–27, 2011 Burr DB: Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 7(4):354–355, 2007
Christodoulou C, Pervena A, Klouvas G, Glani E, Falagas ME, Tsakalis G. et al: Combination of biophosphonates and antioangiogenic factors induces osteonecrosis of the jaw more frequently than biophosponates alone. Oncology 76(3):209-11, 2009
Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M. et al: VEGF Inhibition and Renal Thrombotic Microangiopathy. N Engl J Med 358 (11): 1129–36, 2008
Estilo CL, Fornier M, Farooki A, Carison D, Bohle G 3rd, Huryn JM: Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 26(24):4037-8, 2008 Ferguson W: New treatment of necrosis. Am J Dent Science 1 (series 3): 189, 1868 Fleitas T, Martínez-Sales V, Vila V, Reganon E, Mesado D, Martín M. et al: VEGF and TSP1 levels correlate with prognosis in advanced non-small cell lung cancer. Clin Transl Oncol 2013 Mar 5. [Epub ahead of print]
Greuter S, Schmid F, Ruhstallet T, Thuerlimann B.: Bevacizumab- associated osteonecrosis of the jaw. Ann Oncol 19 (12):2091-2092, 2008
Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I. et al: Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 122:181, 2010
Hopp R.N, Pucci J, Santos-Silva A.R, Jorge J: Osteonecrosis after administration of intravitreous Bevacizumab. J Oral Maxillofac Surg 70:632-635, 2012
Hou J, Tao Y, Jiang YR, Li XX, Gao L: Intravitreal bevacizumab versus triamcinolone acetonide for macular edema due to branch retinal vein occlusion: A matched study. Chin Med J122:2695, 2009
Lim JY, Lee SY, Kim JG, Kim JG, Lee JY, Chung H, Yoon YH.l: Intravitreal bevacizumab alone versus in combination with photodynamic therapy for the treatment of neovascular maculopathy in patients aged 5 years or older: 1-year results of a prospective clinical study. Acta Ophthalmol 90(1):61-7, 2010
Noel HR: A lecture on caries and necrosis of bone. Am J Dent Science1 (3): 425-482, 1868
Pakosch D, Papadimas D, Munding J, Kawa D, Kriwalsky MS : Osteonecrosis of the mandible due to anti-angiogenic agent, bevacizumab. Oral Maxillofac Surg. [Epub ahead of print] 2012
Ravaud A: New challenges in kidney cancer therapy: bevacizumab. Ann Oncol 9:89, 2007
Rosenfeld PJ: Intravitreal Avastin: The low cost alternative to Lucentis. Am J Ophthalmol 142:141, 2006
Rusovici R, Patel CJ, Chalam KV: Bevacizumab inhibits proliferation of choroidal endothelial cells by regulation of the cell cycle. Clinical ophtalmol 7: 321-327, 2013
Santos-Silva AR, Belizario Rosa GA, Castro Junior Gd, Dias RB, Prado Ribeiro AC, Brandao TB: Osteonecrosis of the mandible associated with bvacizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 115 (6):e32-6, 2013
Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Kavan P: Bevacizumab Use for Recurrent High-Grade Glioma at McGill University Hospital. Can J Neurol Sci 40(2):241-6,2013
Schmiegel W, Reinacher-Schick A, Arnold D, Kubicka S, Freier W. et al: Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol. [Epub ahead of print] 2013
Semenza GL: A new weapon for attacking tumor blood vessels. N Engl J Med 358 (19): 2066–7, 2008
Serra E, Paolantonio M, Spoto G, Mastrangelo F, Tetè S, Dolci M: Bevacizumab related ostenecrosis of the jaw. Int J Immunopathol Pharmacol 22(4):1121-3, 2009 Sliesoriaitis S, Tawfik, B: Bevacizumab-induced bowel perforation. J Am Osteop Assoc 111 (7) 437-44, 2011
Troeltzsch Μ, Woodlock Τ, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M: Physiology and Pharmacology of nonbisphosphonate drugs Implicated in osteonecrosis of the jaw. J Can Dent Assoc 78:85, 2012
Van Poznak C: Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer ResTreat 122:189–191, 2010
Xiaolin W, Shen N, Mendoza A, Khnanna C, Helman L: CC1-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of m-TOR/Hil-1α/VEGF Signaling. Neoplasia 8: 394-401, 2006
How to cite this article:
|
View the full-text PDF:
|
| ||